Lacosamide Vivanta

Lacosamide, the active ingredient in Lacosamide Vivanta, is an anticonvulsant presented as an injection for intravenous use. It treats partial‑onset seizures as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamide Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lacosamide is an anticonvulsant indicated for focal seizure disorders and is used as add‑on therapy in epilepsy.

Partial‑onset seizures: reduces seizure frequency when combined with other antiepileptic drugs. Epilepsy (focal epilepsy): improves overall seizure control as adjunctive treatment. Refractory focal epilepsy: provides additional therapeutic option for patients not fully controlled by existing regimens.

Lacosamide may cause a range of adverse reactions, from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial discomfort.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of depressive thoughts. - Anaphylaxis: acute hypersensitivity requiring immediate medical attention.

When prescribing Lacosamide Vivanta, clinicians should consider several safety aspects to minimise risk.

Renal impairment: monitor renal function and adjust therapy as needed. Cardiac conduction disorders: obtain baseline ECG and observe for PR‑interval changes. Pregnancy: risk unknown; use only if potential benefit justifies the risk. Concomitant CNS depressants: watch for enhanced sedation or respiratory depression. Hypersensitivity: discontinue immediately if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with several medicines, influencing its plasma concentration or safety profile.

Major Interactions (Avoid): - Carbamazepine: enzyme induction reduces lacosamide levels, decreasing efficacy. - Phenytoin: strong inducer that lowers lacosamide concentrations. - Other sodium‑channel blockers (e.g., lamotrigine): may increase risk of CNS depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): raise lacosamide levels, requiring dose review. - Hormonal contraceptives: may have reduced effectiveness, consider alternative contraception. - Alcohol: can potentiate sedation and dizziness.